ERBB2 and breast carcinoma: Based on preclinical data demonstrating synergy between cytotoxic agents and trastuzumab, clinical trial designs with chemotherapy combinations demonstrating improved survival helped establish trastuzumab as the standard-of-care treatment for both metastatic and early-stage HER2-positive breast cancer.